Brought to you by 
Ventana to create a companion diagnostic for Pfizer’s Xalkori
19 Jun 2015
Executive Summary
Marking its third deal in less than a week, Roche Diagnostics Corp.’s tissue-based cancer diagnostics unit Ventana Medical Systems Inc. has agreed to develop an automated and standardized immunohistochemistry companion test for Pfizer Inc.’s Xalkori (crizotinib), recently approved and launched in the US for non-small cell lung cancer with mutations in the anaplastic lymphoma tyrosine kinase (ALK) gene. Ventana is also in-licensing an antibody from Cell Signaling Technology Inc. to use in the assay.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ventana to create a companion diagnostic for Pfizer’s Xalkori
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice